Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Current Deferred Revenue for 5 consecutive years, with $3.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue fell 65.04% to $3.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.1 million, a 65.04% decrease, with the full-year FY2024 number at $3.1 million, down 65.04% from a year prior.
  • Current Deferred Revenue was $3.1 million for Q4 2024 at Caribou Biosciences, up from $2.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $25.9 million in Q4 2022 to a low of $50000.0 in Q4 2020.
  • A 5-year average of $8.3 million and a median of $8.7 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 17306.0% in 2021, then plummeted 70.39% in 2024.
  • Caribou Biosciences' Current Deferred Revenue stood at $50000.0 in 2020, then surged by 17306.0% to $8.7 million in 2021, then soared by 197.5% to $25.9 million in 2022, then crashed by 65.44% to $8.9 million in 2023, then plummeted by 65.04% to $3.1 million in 2024.
  • Per Business Quant, the three most recent readings for CRBU's Current Deferred Revenue are $3.1 million (Q4 2024), $2.8 million (Q3 2024), and $8.3 million (Q1 2024).